Company intelligence / Profile preview

Nabriva Therapeutics plc

Ownership: Private
Employees: ~39
Development stage: Other

Overview

Nabriva Therapeutics announced it would wind down operations in January 2023. The company had FDA-approved products including XENLETA (lefamulin) for community-acquired pneumonia and was developing CONTEPO (fosfomycin) for complicated urinary tract infections. The company was unable to generate significant sales despite regulatory approvals.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small moleculesAntibiotics
Industry: Biotech

Drug pipeline

3 assets

lefamulin

Approved

2 more assets in the full pipeline.

Partnerships

Merck & Co. (for SIVEXTRO distribution)Sunovion Pharmaceuticals Canada Inc. (for XENLETA in Canada)Amplity Health (for sales initiatives)

Beyond the preview

Go deeper on Nabriva Therapeutics plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nabriva Therapeutics plc.